Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Analyst Coverage

Below is a list of individual analysts that we are aware of that currently follow Cardiff Oncology. Please note that any opinions, estimates or forecasts regarding Cardiff Oncology, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Cardiff Oncology, Inc or its management. Cardiff Oncology, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Firm Analyst
Cowen M. Frahm
Piper J. Catanzaro, PhD
William Blair A. Hsieh, PhD
H. C. Wainwright R. Selvaraju, PhD; R. Burns
Baird J. Beatty, MD, CFA